CTOs on the Move


 
American Dental is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Mercy Care Plan

At Mercy Healthcare Group we are committed to serving the needs of small businesses. Whether you are self-employed, an independent contractor, or a small employer with up to 50 employees, we can provide health care coverage for you, your employees and

Eastern Ct Health Network

Eastern Ct Health Network is a Manchester, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Trustmark Benefits

Trustmark, through its operating divisions and subsidiaries, offers specialized expertise in voluntary benefits, self-funded health plan design and administration, and the delivery of wellness, fitness, recreation, and injury prevention and treatment programs. Trustmark offers employers of all sizes access to benefit options usually reserved for large companies, combined with the personal service you`d expect from a small firm. Our commitment to building long-term, trusted relationships helps people and businesses thrive. Trustmark: benefits beyond benefits.

CareMax

CareMax Medical Centers are Medicare Advantage facilities with a full complement of health and wellness services for the senior population.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.